随着减重药巨头诺和诺德重磅GLP-1类药物司美格鲁肽在中国的核心分子专利即将于3月到期，一大批中国本土的司美格鲁肽仿制药正在获批路上。据公开信息，目前国内市场上包括九源基因、丽珠集团、华东医药、齐鲁制药、正大天晴在内的十多家本土制药公司的司美格鲁肽仿制药有望在不久的将来上市，还有十余款处于三期临床，一场价格大战即将席卷。一位内分泌专家表示，随着更多仿制药的上市，减重药很快就会迎来“白菜价”时代。（第一财经）
writer.releaseLock();
，更多细节参见Line官方版本下载
9600 bps "loop" interface for a local multidrop serial bus. For larger
Фото: Elena Mayorova / Globallookpress.com
。业内人士推荐heLLoword翻译官方下载作为进阶阅读
Meta's handling of scammy advertisers has come under increased scrutiny in recent months after Reuters reported that researchers at the company at one point estimated that as much as 10 percent of its ad revenue could be coming from scams and banned products. The fact that Meta has made billions of dollars from problematic advertisers has also caused the company to be slow to take action against repeat offenders.，更多细节参见51吃瓜
香港國安警察於2020年12月起訴黎智英欺詐罪，指控黎智英的力高顧問公司在《壹傳媒》與《蘋果日報》報社大樓內運營，違反租契，構成對地主欺詐。